Pharmaceutical Executive
International trade rules play a large role in creating world poverty, according to Oxfam, an international confederation of organizations committed to end poverty. In a recent report, "Rigged Rules and Double Standards," the group accuses rich nations of robbing poor nations of $100 billion a year by abusing trade rules. It also criticizes pharma for enforcing its patents in poor countries.
International trade rules play a large role in creating world poverty, according to Oxfam, an international confederation of organizations committed to end poverty. In a recent report, "Rigged Rules and Double Standards," the group accuses rich nations of robbing poor nations of $100 billion a year by abusing trade rules. It also criticizes pharma for enforcing its patents in poor countries.
One of the major culprits named is the World Trade Organization (WTO) and its rules on intellectual property. The report is particularly scathing in its assessment of the Trade Related Aspects of Intellectual Property Rights Agreement (TRIPs), which aims to ensure that patents are stringently enforced.
Oxfam claims that compliance with TRIPs could cost developing countries $40 billion in increased license payments, half of it to the United States. It calls TRIPs "an act of institutionalized fraud, sanctioned by WTO rules."
The report calls for an end to the universal application of the WTO intellectual property blueprint. It says developing countries should be allowed to maintain more flexible systems of intellectual property protection, such as a restriction of the geographical coverage of patents or greater flexibility in the period of patent protection, with developing countries able to allow periods of 10 years or less, depending on their levels of development and health status. It also calls for a clear commitment to put public health priorities before patent holders' claims, building on the commitments made at the WTO's Doha conference last November.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.